三阴性乳腺癌中miR-135b、LZTS1表达水平对评估新辅助化疗疗效的价值  

The relationships between the expression of miR-135b,LZTS1 in triple-negative breast cancer and the efficacy of neoadjuvant chemotherapy

作　　者：冯燕枝 张景臣[1] 刘薇[1] FENG Yan-zhi;ZHANG Jing-chen;LIU Wei(Department of Mammary Gland,People's Hospital of Zhengzhou,Zhengzhou,Henan 450000,China)

机构地区：[1]郑州人民医院乳腺科,河南郑州450000

出　　处：《热带医学杂志》2020年第4期525-529,566,F0002,共7页Journal of Tropical Medicine

基　　金：郑州市卫生科技发展计划项目(201303219)。

摘　　要：目的探究三阴性乳腺癌(TNBC)中microRNA-135b(miR-135b)、亮氨酸拉链肿瘤抑制基因1(LZTS1)表达与新辅助化疗疗效的关系。方法2012年10月-2014年5月郑州人民医院肿瘤科收治的实施新辅助化疗的82例TNBC患者的病理资料,另选取同期82例因肿块切除术的正常乳腺组织,采用荧光定量PCR(RT-qPCR)、免疫组化分别检测化疗前乳腺组织中miR-135b、LZTS1 mRNA及蛋白表达,分析化疗前miR-135b、LZTS1表达与新辅助化疗疗效的关系;分别采用Pearson法分析TNBC患者化疗前乳腺癌组织中miR-135b、LZTS1 mRNA的相关性,采用Kaplan-Meier法分析miR-135b、LZTS1蛋白水平与TNBC患者5年生存率的关系。结果与正常乳腺组织[(1.11±0.19)、(1.06±0.15)、92.68%]比较,TNBC患者化疗前乳腺癌组织中miR-135b水平(2.84±0.47)增加,LZTS1 mRNA水平(0.38±0.07)及蛋白阳性表达率(39.02%)降低(P<0.05)。与无效组[(2.96±0.51)、5.56%]比较,有效组乳腺癌组织中miR-135b表达水平(2.17±0.43)降低,LZTS1蛋白阳性表达率(48.44%)均增加(P<0.05)。TNBC患者化疗前乳腺癌组织中miR-135b、LZTS1蛋白阳性表达率与淋巴结状态、组织学分级、肿瘤直径及TNM分期有关(P<0.05),miR-135b和LZTS1 mRNA表达水平呈负相关(r=-0.565,P<0.05),miR-135b高表达组患者5年总生存率58.33%(21/36)显著低于低表达组患者[86.96%(40/46)](χ^2=8.873,P=0.003);LZTS1阴性表达组患者5年总生存率62.00%(31/50)显著低于阳性表达组患者[93.75%(30/32)](χ^2=10.325,P=0.001)。结论化疗前乳腺癌组织中miR-135b上调,LZTS1表达下调,与TNBC组织学分级、肿瘤直径及TNM分期及化疗疗效和5年生存率有关,可能对临床新辅助化疗近远期疗效均有一定预测价值。Objective To investigate the relationships between the expressions of microRNA-135 b(miR-135 b)and leucine zipper tumor suppressor gene 1(LZTS1)in triple negative breast cancer(TNBC)and the efficacy of neoadjuvant chemotherapy.Methods Pathological data of 82 TNBC patients receiving neoadjuvant chemotherapy in our oncology department from October 2012 to May 2014 were collected.And 82 normal breast tissues with tumor resection were collected.Fluorescence quantitative PCR(RT-qPCR)and immunohistochemistry were used to detect the expressions of miR-135 b and LZTS1 m RNA in breast tissue before chemotherapy,and the relationships between the expressions of miR-135 b and LZTS1 before chemotherapy and the efficacy of neoadjuvant chemotherapy were analyzed.Pearson method was used to analyze the correlation of miR-135 b and LZTS1 mRNA in breast cancer tissues of TNBC patients before chemotherapy,and Kaplan Meier method was used to analyze the relationship between miR-135 b and LZTS1 protein level and 5-year survival rate of TNBC patients.Results Compared with normal breast tissues[(1.11±0.19),(1.06±0.15),92.68%],the level of miR-135 b(2.84±0.47)in breast cancer tissues of TNBC patients before chemotherapy were higher,while the level of LZTS1 mRNA(0.38±0.07)and the positive expression rate(39.02%)of LZTS1 protein were lower(P<0.05).Compared with the ineffective group[(2.96±0.51),5.56%],the expression level of miR-135 b(2.17±0.43)in breast cancer tissues of TNBC patients in the effective group after chemotherapy was lower,and the positive expression rate of LZTS1 protein(48.44%)was higher(P<0.05).The level of miR-135 b and the positive expression rate of LZTS1 protein in breast cancer tissues of TNBC patients before chemotherapy were related to lymph node status,histological grade,tumor diameter and TNM stage(P<0.05),and the expression levels of miR-135 b and LZTS1 mRNA were significantly negatively correlated(r=-0.565,P<0.05).The 5-year overall survival rate of patients with high expression of miR-135 b in breast canc

关 键 词：三阴性乳腺癌 microRNA-135b 亮氨酸拉链肿瘤抑制基因1 新辅助化疗 

分 类 号：R737.9[医药卫生—肿瘤]